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Abstract
Background: In the diagnosis of celiac disease (CD), serum
assays for anti-endomysium (EMA) and anti-transglutami-
nase (anti-tTG) antibodies have excellent diagnostic accu-
racy. However, these assays are less sensitive in young
pediatric patients. Recently, a new ELISA test using deami-
dated gliadin peptides (DGP) as antigen has proved to be
very sensitive and specific even in pediatric patients. In addi-
tion, anti-actin IgA antibodies (AAA) is another test that can
be used in CD patients because antibody concentrations cor-
relate with the degree of villous atrophy. This study evaluated
the clinical accuracy of anti-tTG, EMA, AGA, anti-DGP and
AAA and the effectiveness of these in different combinations
for diagnosing CD in a large cohort of pediatric patients.
Methods: Sera of 150 children under 6 years of age were
tested: 95 patients had a diagnosis of CD, while 55 patients
who did not suffer from CD were used as controls. Anti-
DGP IgA/IgG and AAA were assayed with ELISA kits,
while anti-tTG IgA/IgG and AGA IgG/IgA were assayed
using a quantitative fluoroimmunoassay. The EMA test was
conducted by indirect immunofluorescence.
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Results: Seventy-six of 95 (80%) CD patients were positive
for DGP IgA and/or tTG IgA. Eighty of 95 (84.2%) patients
were positive for DGP IgG and/or tTG IgA. None of the
controls were positive for these antibodies. Eighty-four of 95
(88.4%) patients and 8/55 (14.5%) controls were positive for
AAA and/or anti-tTG IgA.
Conclusions: In very young children, association of anti-tTG
IgA with anti-DGP IgG is the best test combination for diag-
nosing CD, yielding a cumulative sensitivity of 84.2% and
a specificity of 100%.
Keywords: actin; celiac disease; children; diagnostic accu-
racy; endomysium; gliadin; transglutaminase.
Introduction
Celiac disease (CD) is an immune-mediated enteropathy trig-
gered by gluten ingestion in genetically predisposed individ-
uals. CD is one of the most common gastrointestinal
disorders, with a prevalence of 1:100–1:200 in the general
population (1–3). The large increase in CD diagnosis over
recent decades is in large part due to the availability of
immunoassays with excellent diagnostic accuracy, such as
the IgA anti-transglutaminase (anti-tTG) antibody assay
(4–8). However, discordant data between adults and children
have been reported as the anti-tTG assay is less accurate in
very young patients and autoantibody levels can fluctuate
(9–11). In fact, the reported sensitivity for IgA anti-tTG,
including all ages, ranges between 67% and 100%, with a
specificity between 96% and 100% (5, 11–19), while in very
young patients the sensitivity is lower, with a value ranging
from 67% to 83% (11, 17, 18).
In addition to the anti-tTG assay, commercially available
tests for CD diagnosis include IgA anti-endomysium anti-
bodies (EMA) and IgA and IgG anti-gliadin antibodies (AGA).
EMA sensitivity in children ranges from 83% to 100%
(12, 17, 18, 20), but is lower in children under 2 years of
age, being approximately 85% (17, 18, 20).
AGA, in general, have lower diagnostic accuracy than
anti-tTG and EMA, since these autoantibodies can also be
detected in other enteropathies as well as in healthy individ-
uals (21–25). In children, the sensitivity of IgA AGA ranges
between 52% and 95% with a specificity between 68% and
98%. IgG AGA have sensitivity similar to IgA AGA, but
are affected by much lower specificity (approx. 50%) (12,
20–29).
In 2005, the North American Society for Pediatric Gastro-
enterology, Hepatology and Nutrition (NASPHAGAN)
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issued a guideline for the diagnosis of pediatric CD (30).
Although some pediatric CD patients may test negative for
EMA and for anti-tTG and positive only for AGA (10,
31–33), the use of AGA was no longer recommended,
because of its poor overall diagnostic accuracy. This change
weights methodological and economic factors heavily, but
probably under-values the importance of diagnostic
sensitivity.
Recently, a new generation of AGA tests has been devel-
oped (34–37). Schwertz et al. (38) demonstrated that an
immunoassay based on deamidated synthetic gliadin peptides
(DGP) bound to nitrocellulose filters were recognized by sera
of CD patients. The recognition of the epitopes containing
the sequence QPEQPFP showed high specificity for CD.
These data were subsequently confirmed by Sugai et al. (39).
A clinical study by Tonutti et al. (40) involving a large group
of children with CD, some of whom were anti-tTG negative,
showed that anti-DGP antibodies have very high sensitivity
and specificity.
Anti-actin IgA antibodies (AAA) are other antibodies that
can be found in patients with CD. Recent studies suggest
that the detection of AAA can be useful in diagnosing and
monitoring CD because the antibody concentration is related
to the degree of intestinal damage (41–44). Indeed, AAA are
detectable mainly in CD patients with Marsh 3 lesions
and their presence can be considered a marker of intestinal
atrophy. However, more recent studies have shown that anti-
tTG IgA concentrations also correlate with histopathological
findings in adult and pediatric CD patients (45–51). Subse-
quently, Hill and Holmes (52) have shown that a ratio )10
to the anti-tTG level and the cut-off value is a reliable marker
for the presence of Marsh G2 lesions.
Taken together, eight different assays (considering both the
IgA and the IgG isotype) are currently available to diagnose
and monitor CD, each one of them with its own character-
istics of sensitivity and specificity and each giving different
results in adult and pediatric patients (53). Should we then
use all these tests? Are some of them just redundant, not
providing significant additional information to other tests?
The aim of this study was to evaluate the clinical accuracy
of anti-tTG, AGA, anti-DGP, EMA and AAA, both individ-
ually and in different combinations in a wide cohort of pedi-
atric patients aged -6 years, in order to recommend a panel
of tests providing the best efficiency for diagnosing CD.
Patients and methods
A total of 150 sera were studied: 95 were from consecutive patients
with a new diagnosis of CD made according to the criteria of the
European Society of Pediatric Gastroenterology and Nutrition (54).
All CD patients were aged -6 years (range 1–5.5 years, median
4.1; 31 males and 64 females). The control group (age range
1–6 years, median 4; 22 males and 33 females) included 32 patients
affected by respiratory diseases (allergic asthma and rhinitis) and
23 patients affected by digestive disease: lactose intolerance (ns4),
cow milk protein allergy (ns9), Crohn’s disease (ns5), indeter-
minate colitis (ns2) and autoimmune hepatitis (ns3). All patients
were referred in the years 2004–2009 to the Immunopathology and
Allergy Department of Palermo ‘‘Buccheri La Ferla’’ Hospital or
to the Gastroenterology Department of Palermo ‘‘Di Cristina’’
Children’s Hospital. Sera were frozen at –808C and thawed only
once before the serological assays were performed.
Parents of all the children gave consent for the serological inves-
tigations performed in this study.
Anti-tTG IgA/IgG and AGA IgG/IgA antibodies were detected
with the EliA ImmunoCAP system (Phadia Uppsala, Sweden). The
EMA IgA test was conducted by the indirect immunofluorescence
method on cryostatic sections of monkey esophagus (INOVA) at a
starting dilution of 1:5, which was considered the threshold for
positivity.
Anti-DGP IgA and IgG were assayed with a commercial enzyme
immunoassay (ELISA) method using synthetic deamidated gliadin
peptides containing the antigenic sequence PEQ (Quanta-Lite Gli-
adin IgA II and IgG II, INOVA, San Diego, CA, USA).
Tests for IgA AAA were performed using a commercial ELISA
method (F-Actin Smooth Muscle, INOVA) using an anti-human IgA
conjugate as previously described (44). Assays were performed in
accordance with the manufacturer’s instructions. All sera were tested
also for total IgA by nephelometry (BNII Siemens Healthcare,
Munich, Germany).
Intestinal biopsy
At least three biopsy specimens of the second part of the duodenum
were obtained and prepared as previously described (6). Specimens
were embedded in paraffin and slides were stained with hematoxylin
and eosin and graded by conventional histology according to the
Marsh classification (55–57). Three CD patients showed Marsh 2
histology, six patients Marsh 3a, 29 patients Marsh 3b and 57
patients Marsh 3c.
Statistical analysis
The sensitivity and the specificity of each antibody assay were cal-
culated at the cut-off suggested by the manufacturers (seven units
for anti-tTG IgA and IgG, seven units for AGA IgA and IgG, 20
units for anti-DGP IgA and IgG). Cumulative sensitivity and spec-
ificity, with 95% confidence interval (CI) of different test combi-
nations were also calculated. The positive predictive value (PPV)
and the negative predictive value (NPV) of all the assays and of
their associations were also evaluated. Moreover, the relation
between mean levels of anti-tTG IgA, anti-DGP IgA, anti-DGP IgG
and AAA IgA antibodies and the Marsh’s score was assessed by
means of the univariate analysis of variance (ANOVA) test. Finally,
the rate of positive results of each antibody was evaluated in rela-
tionship to the grade of intestinal atrophy. Statistical analysis was
performed using the Medcalc Software Version 10.4.5 for Windows
statistical package.
Cost of testing
The costs of each single assay and of a combination of assays were
calculated based on the current Italian price list of laboratory tests.
Results
Anti-tTG and EMA assays
Seventy-four of the 95 children with CD (77.9%) were anti-
tTG IgA positive (range, 8.9–150 units) and EMA IgA pos-
itive (range, 1:5–1:1280) (Table 1). The other 21 were
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anti-tTG and EMA negative. Fifty-two of the 74 anti-tTG
IgA positive patients were also anti-tTG IgG positive. All 55
control patients were negative for anti-tTG IgA and IgG.
Anti-tTG IgA antibodies and the Marsh score of intestinal
atrophy were significantly correlated (F-ratio 3.460;
ps0.02). Mean values and standard deviations of anti-tTG
IgA antibodies in the Marsh groups are shown in Table 2.
As regards the correlation between anti-tTG IgA antibody
assay and the severity of intestinal damage, 29 of the Marsh
3c patients (50.9%), 10 of the Marsh 3b patients (34.5%),
one of the Marsh 3a patients (16.7%) and none of the Marsh
two patients had IgA anti-tTG G10= the cut-off. Overall,
40/92 Marsh 3 patients were strongly positive for IgA anti-
tTG (43.5%, 95% CIs33.8–53.2).
AGA and anti-DGP assays
Forty-three of 95 (45.3%) CD patients were AGA IgA posi-
tive, 48/95 (50.5%) were AGA IgG positive, 43/95 (45.3%)
were positive for anti-DGP IgA and 57/95 (60%) for anti-
DGP IgG (Table 1). In the control group, 2/55 patients
(3.6%) were positive for AGA IgA and 14/55 (25.4%) were
positive for AGA IgG. No false-positive results were
observed for anti-DGP IgA and IgG. Anti-DGP IgA and IgG
antibodies and the Marsh score of intestinal atrophy were
significantly correlated (F-ratio 3.821; ps0.013 and 3.090;
ps0.031, respectively). Mean units and standard deviations
of anti-DGP IgA and of anti-DGP IgG antibodies in the
Marsh groups are shown in Table 2.
As regards the correlation between anti-DGP positivity
and the severity of intestinal damage, 42/92 Marsh 3 patients
were positive for anti-DPG IgA (45.7%, 95%
CIs35.9–56.4) and 56/92 for anti-DPG IgG (60.9%, 95%
CIs51.3–70.4).
AAA assay
IgA AAA were positive in 74 of the 95 (77.9%) untreated
CD patients and 21 were negative (Table 1). Among the 32
control patients affected by respiratory diseases, only one
was positive for AAA, whereas in the group with intestinal
diseases, seven of 23 patients were positive. There was no
significant correlation between AAA levels and the Marsh
score (F-ratio 1.801; ps0.153). Mean units and standard
deviations of AAA in the Marsh groups are shown in Table
2. Forty-nine of the Marsh 3c patients (85.9%), 22 of the
Marsh 3b (75.9%), three of the Marsh 3a (50%) and none
of the Marsh 2 patients were AAA positive. Overall, 74/92
Marsh 3 patients were AAA positive (80.4%, 95%
CIs72.7–88.2).
Total IgA assay
None of the sera showed IgA deficiency (total serum IgA
-0.5 mg/L).
Diagnostic accuracy of combined tests
Seventy-six of 95 (80%) CD patients were positive for anti-
DGP IgA and/or anti-tTG IgA. Eighty of 95 (84.2%) CD
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Table 2 Mean values and standard deviation (SD) of anti-tTG IgA, anti-DGP IgA and IgG, and AAA antibody concentrations in relation
to the Marsh score of intestinal atrophy.
Marsh no. tTG-IgA DGP-IgA DGP-IgG AAA-IgA
score Mean units"SD Mean units"SD Mean units"SD Mean units"SD
2 3 13.0"2.6 12.6"1.7 15.3"0.9 3.6"0.5
3a 6 41.5"31.3 13.8"2.5 31.1"24.1 16.1"12.9
3b 29 61.5"41.9 19.6"16.8 31.5"26.8 20.7"17.1
3c 57 80.3"50.8 37.4"33.1 49.2"34.7 26.2"22.0
tTG, anti-tissue transglutaminase antibodies; DGP, anti-deamidated gliadin antibodies; AAA, anti-actin antibodies.
patients were positive for DGP IgG and/or tTG IgA.
Seventy-eight of 95 (82.1%) CD patients and 14/55 (25.4%)
controls were positive for AGA IgG and/or tTG IgA. Sev-
enty-four patients and two controls were positive for AGA
IgA and/or tTG IgA. Seventy-four patients and nine controls
were positive for AGA IgA and/or AAA. Eighty patients and
nine controls were positive for AGA IgG and/or AAA.
Eighty-four patients and eight controls were positive for
AAA and/or tTG IgA. We did not consider the accuracy
value of the combination of EMA IgA with anti-tTG IgG
because all sera that were anti-tTG IgG and EMA positive
were also anti-tTG IgA positive. None of the control patients
were EMA IgA and anti-tTG IgA and/or IgG positive. The
diagnostic performances of AGA, DGP and tTG combined
tests are summarized in Table 3. Association of anti-tTG IgA
with anti-DGP IgG proved to be the best test combination,
with a cumulative sensitivity of 84.2% (95% CIs77.1–91.4)
and a specificity of 100%. The PPV of this combination is
100% and the NPV is 78.6% (95% CIs70.5–86.8).
Cost of testing
Table 4 presents the costs of each single test and of test
combinations.
If only the anti-tTG IgA assay is used as a screening test,
the cost per patient is 715.51.
Given that 74 out of 95 CD patients had positive anti-tTG
IgA test results, the cost for each CD diagnosis in the studied
population is 718.63. However, if we use this single test
approach, the additional cost of testing total serum IgA,
75.03, must be added, since this step is necessary for iden-
tifying subjects with IgA deficit. This brings the total cost
per patient to 719.54 and per diagnosis to 725.08.
If, in the screening profile the anti-DGP IgG test is com-
bined with the anti-tTG IgA test, the total cost is 725.92 per
patient, with six additional patients diagnosed. Using this
approach, the total cost for each diagnosis is 730.78 (an 18%
increase), with no need to test for total serum IgA because
IgA-deficient patients would be identified by the DGP IgG
test.
Discussion
In the last two decades, the use of anti-tTG antibodies as
more accurate markers for CD has largely replaced AGA
testing for CD diagnosis (58). Although AGA testing is not
recommended by the NASPHAGAN guidelines (30), it could
still be considered useful in pediatric patients who test nega-
tive for anti-tTG or in IgA-deficient patients (9, 25, 59, 60)
because the anti-tTG assay has insufficient sensitivity in very
young children.
In recent years it has been shown that the new anti-DGP
ELISA tests using deamidated gliadin peptides as antigen
have a high sensitivity and a specificity comparable to those
of anti-tTG and EMA and higher than AGA (25, 38–40).
In this study we evaluated the diagnostic accuracy of dif-
ferent combinations of several assays in CD diagnosis in a
large series of very young pediatric patients, with the objec-
tive of determining the test, or combination of tests, best able
to ensure the greatest diagnostic efficacy.
We confirmed that the anti-DGP tests have higher speci-
ficity (IgA 100%, IgG 100%) than AGA tests (IgA 96.4%,
IgG 74.6%), as well as higher sensitivity (DGP IgA 45.3%,
IgG 60.0% vs. AGA (IgA 45.3%, IgG 50.5%). In this
respect, it is noteworthy that none of the CD subjects that
were negative for DGP IgG tested positive for AGA (either
IgA or IgG). These findings confirm the widespread opinion
that the AGA test has limited usefulness for the diagnosis of
CD. Our data also showed that in children, EMA and anti-
tTG IgA have an equal diagnostic accuracy, but the anti-tTG
IgA test should be preferred because it is fully automatized
and it is not prone to subjective interpretation.
The most relevant aspect highlighted by our study is that
the combination of anti-tTG IgA with anti-DGP IgG increa-
ses the accuracy for CD diagnosis in very young children.
Indeed, by combining anti-tTG IgA with anti-DGP IgG, the
clinical sensitivity increased from 77.9% of the anti-tTG IgA
alone to 84.2%, maintaining, at the same time, a very high
specificity (100%). The PPV and NPV (100% and 78.6%,
respectively) also indicate that anti-tTG IgA plus anti-DGP
IgG is the best test combination. Our findings are important
because they confirm in a pediatric population the results
obtained by Volta et al. (61) in adult CD patients. Further-
more, although our patient series did not include subjects
with IgA deficiency, a high accuracy of the anti-DGP IgG
assay has been reported in IgA-deficient CD children (62,
63), showing that this combination of diagnostic tests may
enable accurate recognition even of CD patients with IgA
deficiency. Even if the highest sensitivity (88.4%) and NPV
(81.1%) were observed by the association of anti-tTG IgA
and AAA, the specificity of these two combined assays fell
to 85.5%. These findings suggest that the AAA test has limit-
ed usefulness for the diagnosis of CD and are in agreement
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Table 4 Costs of each single test and of test association for the
diagnosis of celiac disease, according to the Italian list of laboratory
tests.
Assays Euro (7)
tTG IgA or IgG 14.51
EMA 14.51
DGP IgA or IgG 11.41
AGA IgA or IgG 11.41
AAA 14.51
Total IgA 5.03
tTG IgAqtotal IgA 19.54
tTG IgAqDGP IgG 25.92
tTG IgAqAAA 29.02
DGP IgGqAAA 25.92
tTG IgAqDGP IgAqAAA 40.43
EMA, anti-endomysium antibodies; tTG, anti-tissue transglutami-
nase antibodies; DGP, anti-deamidated gliadin antibodies; AGA,
anti-gliadin antibodies; AAA, anti-actin antibodies.
with those reported by previous studies that showed that the
AAA assay cannot replace EMA and anti-tTG in the diag-
nostic algorithm of CD (43, 44, 59). We confirm, however,
that AAA positivity is associated with severe intestinal dam-
age, as reported by other researchers (41–44). Therefore, in
the follow-up of pediatric patients with CD (i.e., monitoring
the adherence to gluten-free diet), the AAA test may provide
important information about mucosal status without the use
of an invasive procedure (64–68). Regarding the possible use
of elevated anti-tTG IgA levels as markers of severe histo-
logical damage, we confirm the data obtained by Donaldson
et al. (48, 49) and Hill and Holmes (52), showing that all
patients with elevated anti-tTG IgA concentrations had
Marsh 3 intestinal atrophy.
In conclusion, our data suggest that the best serological
approach to diagnosing CD in pediatric patients is based on
combining anti-tTG IgA and anti-DGP IgG assays, with only
a moderate increase of screening costs. These tests may be
performed either simultaneously or sequentially. Simultane-
ous testing would probably be more straightforward and
guarantee a faster turn-around time. A sequential approach,
based on a reflex strategy (i.e., testing for anti-DGP IgG only
in patients who test negative for anti-tTG IgA) could contain
costs and be equally effective if supported by reflex testing
automation. The use of AAA could be limited to support the
diagnosis of CD when histological findings are controversial
or to evaluate the adherence to diet of CD patients (44, 69).
However, more data are warranted before their use in these
particular situations could be recommended.
Conflict of interest statement
Authors’ conflict of interest disclosure: The authors declare that
this study was not financially supported by any pharmaceutical
organization or industry.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
6 Brusca et al.: Old and new tests for celiac disease
Article in press - uncorrected proof
References
1. Carlsson AK, Axelsson IE, Borulf SK, Bredberg AC, Ivarsson
SA. Serological screening for celiac disease in healthy 2.5-year-
old children in Sweden. Pediatric 2001;107:42–5.
2. Not T, Horvath K, Hill I, Partanen J, Hammed A, Magazzu G,
et al. Celiac disease risk in the USA: high prevalence of anti-
endomysium antibodies in healthy blood donors. Scand J Gas-
troenterol 1998;33:494–8.
3. Catassi C, Ratsch IM, Fabiani E, Rossini M, Bordicchia F,
Candela F. Celiac disease in the year 2000: exploring the ice-
berg. Lancet 1994;343:200–3.
4. Ferreira M, Davies SL, Butler M, Scott D, Clark M, Kumar P.
Endomysial antibody: is it the best screening test for coeliac
disease? Gut 1992;33:1633–7.
5. Dieterich W, Laag E, Scho¨pper H, Volta U, Ferguson A, Gillett
H, et al. Autoantibodies to tissue transglutaminase as predictors
of celiac disease. Gastroenterology 1998;115:1317–21.
6. Carroccio A, Vitale G, Di Prima L, Chifari N, Napoli S, La
Russa C, et al. Comparison of anti-transglutaminase ELISAs
and anti-endomysial antibody assay in the diagnosis of celiac
disease: a prospective study. Clin Chem 2002;48:1546–50.
7. Reeves GE, Squance ML, Duggan AE, Murugasu RR, Wilson
RJ, Wong RC, et al. Diagnostic accuracy of coeliac serological
tests: a prospective study. Eur J Gastroenterol Hepatol 2006;18:
493–501.
8. Basso D, Guariso G, Plebani M. Serologic testing for celiac
disease. Clin Chem 2002;48:2082–3.
9. Hoffenberg EJ, MacKenzie T, Barriga KJ, Eisenbarth GS, Bao
F, Haas JE, et al. A prospective study of the incidence of child-
hood celiac disease. J Pediatr 2003;143:308–14.
10. Simell S, Kupila A, Hoppu S, Hekkala A, Simell T, Sta˚hlberg
MR, et al. Natural history of transglutaminase autoantibodies
and mucosal changes in children carrying HLA-conferred celiac
disease susceptibility. Scand J Gastroenterol 2005;40:1182–91.
11. Panetta F, Torre G, Colistro F, Ferretti F, Daniele A, Diamanti
A. Clinical accuracy of anti-tissue transglutaminase as screen-
ing test for celiac disease under 2 years. Acta Paediatr 2011;
100:728–31.
12. Vitoria JC, Arrieta A, Arranz C, Ayesta A, Sojo A, Maruri N,
et al. Antibodies to gliadin, endomysium, and tissue transglu-
taminase for the diagnosis of celiac disease. J Pediatr Gastroen-
terol Nutr 1999;29:571–4.
13. Bonamico M, Tiberti C, Picarelli A, Mariani P, Rossi D,
Cipolletta E, et al. Radioimmunoassay to detect antitransglu-
taminase autoantibodies is the most sensitive and specific
screening method for celiac disease. Am J Gastroenterol 2001;
96:1536–40.
14. Baldas V, Tommasini A, Trevisiol C, Berti I, Fasano A,
Sblattero D, et al. Development of a novel rapid non-invasive
screening test for coeliac disease. Gut 2000;47:628–31.
15. Stern M. Comparative evaluation of serologic tests for celiac
disease: a European initiative toward standardization. J Pediatr
Gastroenterol Nutr 2000;31:513–9.
16. Sulkanen S, Halttunen T, Laurilla K, Kolho K. Tissue transglu-
taminase autoantibody enzyme-linked immunosorbent assay in
detecting celiac disease. Gastroenterology 1998;115:1322–8.
17. Mankai A, Sakly W, Landolsi H, Gueddah L, Sriha B, Ayadi
A, et al. Tissue transglutaminase antibodies in celiac disease,
comparison of an enzyme linked immunosorbent assay and a
dot blot assay. Pathol Biol 2005;53:204–9.
18. Lagerqvist C, Dahlbom I, Hansson T, Jidell E, Juto P, Olce´n P,
et al. Anti gliadin immunoglobulin A best in finding celiac
disease in children younger than 18 months of age. J Pediatr
Gastroenterol Nutr 2008;47:428–35.
19. Van Meensel B, Hiele M, Hoffman I, Vermeire S, Rutgeerts P,
Geboes K, et al. Diagnostic accuracy of ten second-generation
(human) tissue transglutaminase antibody assays in celiac dis-
ease. Clin Chem 2004;50:2125–35.
20. Burgin-Wolff A, Gaze H, Hadziselimovic F, Huber H, Lentze
MJ, Nussle´ D, et al. Antigliadin and antiendomysium antibody
determination for coeliac disease. Arch Dis Child 1991;66:
941–7.
21. Bode S, Weile B, Krasilnikoff PA, Gudmand-Hoyer E. The
diagnostic value of the gliadin antibody test in celiac disease
in children: a prospective study. J Pediatr Gastroenterol Nutr
1993;17:260–4.
22. Carroccio A, Iacono G, Montalto G, Cavataio F, Soresi M,
Kazmierska I, et al. Immunologic and absorptive tests in celiac
disease: can they replace intestinal biopsies? Scand J Gastroen-
terol 1993;28:673–6.
23. Berger R, Schmidt G. Evaluation of six anti-gliadin antibody
assays. J Immunol Methods 1996;191:77–86.
24. Rostom A, Dube´ C, Cranney A, Saloojee N, Sy R, Garritty C,
et al. The diagnostic accuracy of serological test for celiac dis-
ease: a systematic review. Gastroenterology 2005;128:S38–46.
25. Laass MW, Koch T, Lo¨sel A, Conrad K, Henker J. Longitudinal
follow-up examination of antigliadin antibody positive children
and adults. Eur J Gastroenterol Hepatol 2006;18:503–6.
26. Burgin-Wolff A, Berger R, Gaze H, Huber H, Lentze MJ,
Nussle D. IgG, IgA and IgE gliadin antibody determinations as
screening test for untreated coeliac disease in children, a mul-
ticentre study. Eur J Pediatr 1989;148:496–502.
27. De Lecea A, Ribes-Koninckx C, Polanco I, Calvete JF. Sero-
logical screening (antigliadin and antiendomysium antibodies)
for nonovert coeliac disease in children of short stature. Acta
Paediatr Suppl 1996;412:54–5.
28. Lerner A, Kumar V, Iancu TC. Immunological diagnosis of
childhood coeliac disease: comparison between antigliadin,
antireticulin and antiendomysial antibodies. Clin Exp Immunol
1994;95:78–82.
29. Sacchetti L, Ferrajolo A, Salerno G, Esposito P, Lofrano MM,
Oriani G, et al. Diagnostic value of various serum antibodies
detected by diverse methods in childhood celiac disease. Clin
Chem 1996;42:1838–42.
30. Hill ID, Dirks MH, Liptak GS, Colletti RB, Fasano A. Guide-
line for the diagnosis and treatment of celiac disease in chil-
dren: recommendations of the North American Society for
Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr
Gastroenterol Nutr 2005;40:1–19.
31. Bottaro G, Volta U, Spina M, Rotolo N, Sciacca A, Musumeci
S. Antibody pattern in childhood celiac disease. J Pediatr Gas-
troenterol Nutr 1997;24:559–62.
32. Savilahti E, Viander M, Perkkio¨ M, Vainio E, Kalimo K,
Reunala T. IgA antigliadin antibodies: a marker of mucosa
damage in childhood coeliac disease. Lancet 1983;12:320–2.
33. Tonutti E, Visentini D, Bizzaro N, Caradonna M, Cerni L,
Villalta D, et al. The role of anti-tissue transglutaminase assay
for the diagnosis and monitoring of coeliac disease: a French-
Italian multicentre study. J Clin Pathol 2003;56:389–93.
34. Koning F. Celiac disease: caught between a rock and a hard
place. Gastroenterology 2005;129:1294–301.
35. Aleanzi M, Demonte AM, Esper C, Garcilazo S, Waggener M.
Celiac disease: antibody recognition against native and selec-
tively deamidated gliadin peptides. Clin Chem 2001;47:
2023–8.
Brusca et al.: Old and new tests for celiac disease 7
Article in press - uncorrected proof
36. Sjo¨stro¨m H, Lundin KE, Molberg O, Ko¨rner R, McAdam SN,
Anthonsen D, et al. Identification of a gliadin T-cell epitope in
coeliac disease: general importance of gliadin deamidation for
intestinal T-cell recognition. Scand J Immunol 1998;48:111–5.
37. Molberg O, Mcadam SN, Ko¨rner R, Quarsten H, Kristiansen
C, Madsen L, et al. Tissue transglutaminase selectively modi-
fies gliadin peptides that are recognized by gut derived T cells
in celiac disease. Nat Med 1998;4:713–7.
38. Schwertz E, Kahlenberg F, Sack U, Richter T, Stern M, Conrad
K, et al. Serologic assay based on gliadin-related nonapeptides
as a highly sensitive and specific diagnostic aid in celiac dis-
ease. Clin Chem 2004;50:2370–5.
39. Sugai E, Va´zquez H, Nachman F, Moreno ML, Mazure R,
Smecuol E, et al. Accuracy of testing for antibodies to synthetic
gliadin-peptides in celiac disease. Clin Gastroenterol Hepatol
2006;4:1112–7.
40. Tonutti E, Visentini D, Picierno A, Bizzaro N, Villalta D,
Tozzoli R, et al. Diagnostic efficacy of the ELISA test for the
detection of deamidated anti-gliadin peptide antibodies in the
diagnosis and monitoring of celiac disease. J Clin Lab Anal
2009;23:165–71.
41. Clemente MG, Musu MP, Frau F, Brusco G, Sole G, Corazza
GR, et al. Immune reaction against the cytoskeleton in celiac
disease. Gut 2000;47:520–6.
42. Clemente MG, Musu MP, Troncone R, Volta U, Congia M,
Ciacci C, et al. Enterocyte actin antibody detection: a new diag-
nostic tool in celiac disease diagnosis: results of a multicenter
study. Am J Gastroenterol 2004;99:1551–6.
43. Carroccio A, Brusca I, Iacono G, Di Prima L, Teresi S, Pirrone
G, et al. Anti-actin antibodies in celiac disease: correlation with
intestinal mucosa damage and comparison of ELISA with the
immunofluorescence assay. Clin Chem 2005;51:917–20.
44. Carroccio A, Brusca I, Iacono G, Alessio MG, Sonzogni A, Di
Prima L, et al. IgA anti-actin antibodies ELISA in coeliac dis-
ease: a multicentre study. Dig Liver Dis 2007;39:818–23.
45. Hoffenberg EJ, Bao F, Eisenbarth GS, Uhlhorn C, Haas JE,
Sokol RJ, et al. Transglutaminase antibodies in children with a
genetic risk for celiac disease. J Pediatr 2000;137:356–60.
46. Tursi A, Brandimarte G, Giorgetti GM. Prevalence of antitissue
transglutaminase antibodies in different degrees of intestinal
damage in celiac disease. J Clin Gastroenterol 2003;36:219–21.
47. Jatla M, Bokhari A, Bierly P, Russo P, Verma R. Anthropo-
metric, serologic, and laboratory correlation with villous blunt-
ing in pediatric celiac disease: diabetics are different. J Clin
Gastroenterol 2009;43:622–6.
48. Donaldson MR, Firth SD, Wimpee H, Leiferman KM, Zone JJ,
Horsley W, et al. Correlation of duodenal histology with tissue
transglutaminase and endomysial antibody levels in pediatric
celiac disease. Clin Gastroenterol Hepatol 2007;5:567–73.
49. Donaldson MR, Book LS, Leiferman KM, Zone JJ, Neuhausen
SL. Strongly positive tissue transglutaminase antibodies are
associated with Marsh 3 histopathology in adult and pediatric
celiac disease. J Clin Gastroenterol 2008;42:256–60.
50. Barker CC, Mitton C, Jevon G, Mock T. Can tissue transglu-
taminase antibody titers replace small bowel biopsy to diagnose
celiac disease in selected pediatric populations? Pediatrics
2005;115:1341–6.
51. Diamanti A, Colistro F, Calce A, Devito R, Ferretti F, Minozzi
A, et al. Clinical value of immunoglobulin A antitransgluta-
minase assay in the diagnosis of celiac disease. Pediatrics
2006;118:1696–700.
52. Hill PG, Holmes KT. Coeliac disease: a biopsy is not always
necessary for diagnosis. Alim Pharmacol Ther 2008;27:572–7.
53. Bizzaro N, Tozzoli R, Villalta D, Fabris M, Tonutti E. Cutting
edge issues in celiac disease and in gluten intolerance. Clin Rev
Allergy Immunol 2010;23. wEpub ahead of printx.
54. Revised criteria for diagnosis of coeliac disease. Report of
Working Group of European Society of Paediatric Gastroenter-
ology and Nutrition. Arch Dis Child 1990;65:909–11.
55. Marsh MN, Crowe PT. Morphology of the mucosal lesion in
gluten sensitivity. Baillie`re’s Clin Gastroenterol 1995;9:273–93.
56. Oberhuber G, Granditsch G, Vogelsang H. The histopathology
of celiac disease: time for a standardized report scheme for
pathologists. Eur J Gastroenterol Hepatol 1999;11:1185–94.
57. Antonioli DA. Celiac disease: a progress report. Mod Pathol
2003;16:342–6.
58. Lock RJ, Pitcher MC, Unsworth DJ. IgA anti-tissue transglu-
taminase as diagnostic marker of gluten sensitive enteropathy.
J Clin Pathol 1999;52:274–7.
59. Granito A, Muratori P, Cassani F, Pappas G, Muratori L,
Agostinelli D, et al. Anti-actin IgA antibodies in severe coeliac
disease. Clin Exp Immunol 2004;137:386–92.
60. Lenhardt A, Plebani A, Marchetti F, Gerarduzzi T, Not T, Meini
A, et al. Role of human-tissue transglutaminase IgG and anti-
gliadin IgG antibodies in the diagnosis of coeliac disease in
patients with selective immunoglobulin A deficiency. Dig Liver
Dis 2004;36:730–4.
61. Volta U, Fabbri A, Parisi C. Deamidated gliadin peptide anti-
bodies as a routine test for celiac disease: a prospective anal-
ysis. J Clin Gastroenterol 2010;44:186–90.
62. Villalta D, Alessio MG, Tampoia M, Tonutti E, Brusca I,
Bagnasco M, et al. Testing for IgG class antibodies in celiac
disease patients with selective IgA deficiency. A comparison of
the diagnostic accuracy of 9 IgG anti-tissue transglutaminase,
1 IgG anti-gliadin and 1 IgG anti-deaminated gliadin peptide
antibody assays. Clin Chim Acta 2007;382:95–9.
63. Villalta D, Tonutti E, Prause C, Koletzko S, Uhlig HH,
Vermeersch P, et al. IgG antibodies against deamidated gliadin
peptides for diagnosis of celiac disease in patients with IgA
deficiency. Clin Chem 2010;56:464–8.
64. Guandalini S, Gupta P. Do you still need a biopsy to diagnose
celiac disease? Curr Gastroenterol Rep 2001;3:385–91.
65. Scoglio R, Di Pasquale G, Pagano G, Lucanto MC, Magazzu`
G, Sferlazzas C. Is intestinal biopsy always needed for diag-
nosis of celiac disease? Am J Gastroenterol 2003;98:1325–31.
66. Murdock AM, Johnston SD. Diagnostic criteria for coeliac dis-
ease: time for change? Eur J Gastroenterol Hepatol 2005;
17:41–3.
67. Barker CC, Mitton C, Jevon G, Mock T. Can tissue transglu-
taminase antibody titers replace small-bowel biopsy to diagnose
celiac disease in select pediatric populations? Pediatrics
2005;115:1341–6.
68. Sugai E, Moreno ML, Hwang HJ, Cabanne A, Crivelli A,
Nachman F, et al. Celiac disease serology in patients with dif-
ferent pretest probabilities: is biopsy avoidable? World J Gas-
troenterol 2010;16:3144–52.
69. Bazzigaluppi E, Parma B, Tronconi GM, Corsin P, Albarello L,
Mora S, et al. IgA anti-Actin antibodies in children with celiac
disease: comparison of immunofluorescence with Elisa assay in
predicting severe intestinal damage. It J Pediatrics 2010;36:25.
